DVN’s 2025 Annual General Meeting
|
At the meeting, Ms. Han Thi Khanh Vinh, Member of the Board of Directors and General Director of DVN, shared that the pharmaceutical distribution sector in 2024 experienced slower growth compared to the previous year, with the highest growth rate observed in patented drugs. Additionally, the ETC market share for high-quality drugs in Groups 1 and 2 faced intense competition between domestically produced and imported products.
In 2024, DVN’s consolidated total revenue reached VND 5,812 billion, a slight decrease from the previous year, achieving 98% of the set plan. Consolidated pre-tax profit reached VND 509 billion, a 24% increase from the previous year, surpassing the plan by 7%.
With these results, the DVN Board of Directors proposed and received shareholder approval for a 2024 dividend payout of 10% of charter capital.
Plans to Increase Ownership in Sanofi Vietnam to 30%
For 2025, DVN sets a target of VND 5,970 billion in consolidated total revenue and VND 465 billion in pre-tax profit. This plan is based on the assumption that DVN will increase its ownership in Sanofi Vietnam from 15% to 30% in Q2/2025.
Ms. Han Thi Khanh Vinh – Member of the Board of Directors and General Director of DVN
|
According to General Director Han Thi Khanh Vinh, DVN has been working diligently with its partner to finalize the process of increasing its ownership in SVN to 30% in Q2/2025, thereby making SVN a subsidiary of DVN.
Additionally, DVN aims to collaborate with pharmaceutical and biopharmaceutical corporations from Europe, the US, and several regional countries. These partnerships are intended to explore opportunities for technology transfer, construct pharmaceutical/biopharmaceutical facilities in Vietnam, and distribute high-quality products in the Vietnamese market.
In 2024, DVN and the Korean pharmaceutical group Celltrion signed a Memorandum of Understanding for cooperation in the field of biopharmaceuticals. “The Corporation is continuing negotiations with Celltrion to materialize the contents of the signed MoU, including accelerating the process of signing an exclusive distribution contract for Celltrion’s products in the Vietnamese market,” said Ms. Vinh.
The meeting also approved the election of Mr. Nguyen Tien Dung as a supplementary member of the Board of Directors for the 2021-2026 term.
Phuong Chau
– 16:07 21/04/2025
